专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010105035A2 PREVENTION, TREATMENT, AND DIAGNOSIS OF ALZHEIMER'S DISEASE THROUGH ELECTROMAGNETIC FIELD EXPOSURE 审中-公开
标题翻译：通过电磁场暴露预防，治疗和诊断阿尔茨海默病
公开(公告)号：WO2010105035A2
公开(公告)日：2010-09-16
申请号：PCT/US2010026952
申请日：2010-03-11
申请人： UNIV SOUTH FLORIDA , ARENDASH GARY W , CAO CHUANHAI , TAN JUN
发明人： ARENDASH GARY W , CAO CHUANHAI , TAN JUN
IPC分类号： A61N2/02 , A61N5/00
CPC分类号： A61N5/02 , A61N2/006 , A61N2/02
摘要： According to a first embodiment the invention includes a method of treating a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. The predetermined frequency, according to a preferred embodiment, is about918 MGH with a specific absorption rate (SAR) of about 0.25 W/kg +/-2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.
摘要翻译：根据第一实施方案，本发明包括通过将电磁场发射源定位在受试者的近侧并将受试者暴露于具有预定频率的电磁场的方式来治疗有需要的受试者中的神经系统疾病如阿尔茨海默病达到预定的吸收周期。优选地，每个单独的处理（包括以预定的频率暴露预定的吸收期）以预定的时间表（优选地每天）持续预定的治疗期。根据优选实施例，预定频率为大约918MGH，比吸收率（SAR）为约0.25W / kg +/- 2dB。该优选实施方案的预定吸收周期为约1小时。治疗期是长期的，大于约6个月，优选约7-9个月。

2. 发明申请

WO2009023814A3 HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE 审中-公开
标题翻译： HUCBC治疗AMYLOID相关疾病
公开(公告)号：WO2009023814A3
公开(公告)日：2009-05-07
申请号：PCT/US2008073265
申请日：2008-08-15
申请人： UNIV SOUTH FLORIDA , TAN JUN , SANBERG PAUL R
发明人： TAN JUN , SANBERG PAUL R
IPC分类号： A61K35/14
CPC分类号： A61K35/16 , A61K35/44 , A61K2035/122
摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble AB protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of AB 1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
摘要翻译：人类脐带血细胞（HUCBC）或HUCBC衍生的血浆的施用用于治疗淀粉样疾病，例如阿尔茨海默氏病，亨廷顿舞蹈病，脑淀粉样蛋白抗肌病和II型糖尿病。通过输注HUCBC来调节炎症反应导致淀粉样斑块和免疫相关细胞损伤的显着减少。 HUCBC输注也显着减少小鼠模型中的脑淀粉样血管病。这些作用与抑制CD40-CD40L相互作用有关，并且在免疫细胞上观察到表面表达CD-40的减少。此外，A？吞噬活性增加，可溶性和不溶性AB蛋白水平通过治疗被调节。注射HUCBC的血清也显着增加AB 1-42肽的吞噬作用并抑制免疫细胞CD40表达并减少脑淀粉样血管病。

3. 发明申请

WO0236166A8 COMPOSITIONS FOR STIMULATING CD45 AND THEREBY SUPPRESSING MICROGLIAL ACTIVATION ASSOCIATED WITH ALZHEIMER'S DISEASE 审中-公开
标题翻译：刺激CD45及其抑制与阿尔茨海默病相关的微粒子活化的组合物
公开(公告)号：WO0236166A8
公开(公告)日：2003-03-20
申请号：PCT/US0142909
申请日：2001-11-05
申请人： UNIV SOUTH FLORIDA , TAN JUN , TOWN TERRENCE , MULLAN MICHAEL
发明人： TAN JUN , TOWN TERRENCE , MULLAN MICHAEL
IPC分类号： A61K38/17 , A61P25/28 , C07K16/28 , G01N33/50 , G01N33/68 , A61K39/395
CPC分类号： G01N33/6896 , A61K38/1709 , C07K16/289 , G01N33/5047 , G01N2333/4709 , G01N2800/2821 , A61K2300/00
摘要： A method of inhibiting the negative effects of beta-amyloid in the brain of an animal comprising administering an effective amount of a compound that modulates CD45 activity. This invention also relates to compositions for use in stimulating CD45, and assays for une in finding compounds useful in inhibiting the negative effects of beta-amyloid. An assay for use in identifying compounds that inhibit the negative effects of beta-amyloid comprises (a) contacting immune cells with a predetermined amount of one or more test compounds in the presence of beta-amyloid or one or more peptides derived therefrom, (b) monitoring the amount of one or more inflammatory molecules released by the immune cells, and (c) comparing the amount found in step (b) with another amount found in the absence of the one or more test compounds or using a different predetermined amount the one or more test compounds.
摘要翻译：抑制动物脑中β-淀粉样蛋白的负面影响的方法，包括给药有效量的调节CD45活性的化合物。本发明还涉及用于刺激CD45的组合物和用于发现可用于抑制β-淀粉样蛋白的负面作用的化合物的测定。用于鉴定抑制β-淀粉状蛋白的负面影响的化合物的测定法包括（a）在存在β-淀粉样蛋白或一种或多种由其衍生的肽的情况下，使预定量的一种或多种测试化合物与免疫细胞接触，（b ）监测由免疫细胞释放的一种或多种炎性分子的量，和（c）将步骤（b）中发现的量与不存在一种或多种测试化合物时发现的另一量相比较，或者使用不同的预定量一种或多种测试化合物。

4. 发明申请

WO2005013910A3 CHOLINERGIC MODULATION OF MICROGLIAL ACTIVATION VIA ALPHA-7 NICOTINIC RECEPTORS 审中-公开
标题翻译：通过ALPHA-7 NICOTINIC受体进行微量激活的胆固醇调节
公开(公告)号：WO2005013910A3
公开(公告)日：2005-04-28
申请号：PCT/US2004025714
申请日：2004-08-09
申请人： UNIV SOUTH FLORIDA , SHYTLE DOUGLAS , TAN JUN , SANBERG PAUL R
发明人： SHYTLE DOUGLAS , TAN JUN , SANBERG PAUL R
IPC分类号： A61K20060101 , A61K31/24 , A61K31/44
CPC分类号： A61K31/44 , A61K31/13 , A61K31/24 , A61K38/1703 , A61K45/06 , A61K2300/00
摘要： Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as those chosen from the group consisting of acetycholine, nicotine, choline, galantamine, cytisine, GTS-21, or derivatives thereof, wherein the target cell is a microglia is provided.
摘要翻译：治疗神经免疫和神经退行性疾病的新型治疗靶点。因此，治疗患者神经变性疾病的方法以及抑制促炎细胞因子的释放，包括使靶细胞与治疗有效量的胆碱能激动剂例如选自以下的那些接触的步骤：乙酰胆碱，尼古丁，胆碱，加兰他敏，仙子碱，GTS-21或其衍生物，其中靶细胞是小胶质细胞。

5. 发明申请

WO0236166A2 METHODS AND COMPOSITIONS FOR STIMULATING CD45 AND THEREBY SUPPRESSING MICROGLIAL ACTIVATION ASSOCIATED WITH ALZHEIMER'S DISEASE 审中-公开
标题翻译：用于刺激CD45的方法和组合物，抑制与阿尔茨海默病相关的微量激活
公开(公告)号：WO0236166A2
公开(公告)日：2002-05-10
申请号：PCT/US0142909
申请日：2001-11-05
申请人： UNIV SOUTH FLORIDA , TAN JUN , TOWN TERRENCE , MULLAN MICHAEL
发明人： TAN JUN , TOWN TERRENCE , MULLAN MICHAEL
IPC分类号： A61K38/17 , A61P25/28 , C07K16/28 , G01N33/50 , G01N33/68 , A61K45/00
CPC分类号： G01N33/6896 , A61K38/1709 , C07K16/289 , G01N33/5047 , G01N2333/4709 , G01N2800/2821 , A61K2300/00
摘要： A method of inhibiting the negative effects of beta-amyloid in the brain of an animal comprising administering an effective amount of a compound that modulates CD45 activity. This invention also relates to compositions for use in stimulating CD45, and assays for une in finding compounds useful in inhibiting the negative effects of beta-amyloid. An assay for use in identifying compounds that inhibit the negative effects of beta-amyloid comprises (a) contacting immune cells with a predetermined amount of one or more test compounds in the presence of beta-amyloid or one or more peptides derived therefrom, (b) monitoring the amount of one or more inflammatory molecules released by the immune cells, and (c) comparing the amount found in step (b) with another amount found in the absence of the one or more test compounds or using a different predetermined amount the one or more test compounds.
摘要翻译：一种抑制动物脑中β-淀粉样蛋白的负面影响的方法，包括给予有效量的调节CD45活性的化合物。本发明还涉及用于刺激CD45的组合物，以及用于寻找可用于抑制β-淀粉样蛋白的负面作用的化合物的测定。用于鉴定抑制β-淀粉样蛋白的负面作用的化合物的测定法包括（a）在β-淀粉样蛋白或一种或多种衍生自其的肽的存在下使免疫细胞与预定量的一种或多种测试化合物接触，（b ）监测由免疫细胞释放的一种或多种炎症分子的量，和（c）将在步骤（b）中发现的量与在一种或多种测试化合物不存在或使用不同的预定量的情况下发现的另一量进行比较一种或多种测试化合物。

6. 发明申请

WO2012047341A2 SAPP-ALPHA AS A BIOMARKER FOR PREDICTION OF INFLAMMATORY AND AUTOIMMUNE-RELATED DISORDERS 审中-公开
标题翻译： SAPP-ALPHA作为预防炎症和自身免疫相关疾病的生物标志物
公开(公告)号：WO2012047341A2
公开(公告)日：2012-04-12
申请号：PCT/US2011042648
申请日：2011-06-30
申请人： UNIV SOUTH FLORIDA , TAN JUN , OBREGON DEMIAN , BAILEY ANTOINETTE
发明人： TAN JUN , OBREGON DEMIAN , BAILEY ANTOINETTE
CPC分类号： G01N33/5091 , G01N33/564 , G01N2333/705 , G01N2800/50
摘要： The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-a) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders.
摘要翻译：本发明涉及淀粉样蛋白前体蛋白α（sAPP-a）用作生物标志物用于预测受试者发生炎症和/或自身免疫相关疾病的风险的用途。此外，本发明提供了优化疫苗时间表和组合物的方法，从而预防或降低疫苗诱导的炎症和/或自身免疫相关疾病的风险。

7. 发明申请

WO2008109521A3 METHOD OF TREATMENT USING ATRANORIN 审中-公开
标题翻译：使用ATRANORIN治疗方法
公开(公告)号：WO2008109521A3
公开(公告)日：2008-12-24
申请号：PCT/US2008055655
申请日：2008-03-03
申请人： UNIV SOUTH FLORIDA , TAN JUN , SHYTLE ROLAND DOUGLAS , OBREGON DEMIAN
发明人： TAN JUN , SHYTLE ROLAND DOUGLAS , OBREGON DEMIAN
IPC分类号： C11B9/02
CPC分类号： A61K31/353 , A61K31/7048 , A61K36/09 , A61K2300/00
摘要： Disclosed herein is a method of treating a neurodegenerative disease, comprising the step of administering a therapeutically effective amount of Atranorin, or a closely related compound thereof. The neurodegenerative disease is Alzheimer's disease in one embodiment. The closely related compound is selected from the group consisting of chloroatranorin, evernic acid, barbatic acid, 4-O-demethyl-barbatic acid, lecanoric acid, diffratic acid and gyrophoric acid. Also disclosed is a method of treating a cellular proliferative disease, comprising the step of administering a therapeutically effective amount of Atranorin, or a closely related compound thereof. The cellular proliferative disease is cancer in one embodiment. The method of claim 1 wherein the closely related compound is selected from the group consisting of chloroatranorin, evernic acid, barbatic acid, 4-O-demethyl-barbatic acid, lecanoric acid, diffratic acid and gyrophoric acid
摘要翻译：本文公开了一种治疗神经退行性疾病的方法，其包括施用治疗有效量的阿特兰林或其紧密相关化合物的步骤。在一个实施方案中，神经变性疾病是阿尔茨海默氏病。密切相关的化合物选自氯丙酰胺，海藻酸，巴氏酸，4-O-去甲基 - 酸性酸，氨磺酸，异柠檬酸和旋花酸。还公开了一种治疗细胞增殖性疾病的方法，其包括施用治疗有效量的阿特兰林或其紧密相关的化合物的步骤。在一个实施方案中，细胞增殖性疾病是癌症。 2.根据权利要求1所述的方法，其中所述紧密相关的化合物选自氯化氨基葡萄糖苷，海藻酸，巴氏酸，4-O-去甲基 - 酸性酸，左旋肉碱酸，异柠檬酸和富马酸

8. 发明申请

WO0178769A3 REGULATION OF SYSTEMIC IMMUNE RESPONSES UTILIZING SOLUBLE CD40 审中-公开
标题翻译：使用可溶性CD40的系统性免疫应答的调节
公开(公告)号：WO0178769A3
公开(公告)日：2002-02-28
申请号：PCT/US0112003
申请日：2001-04-12
申请人： UNIV SOUTH FLORIDA , YU HUA , TURNER JOEL G , TAN JUN
发明人： YU HUA , TURNER JOEL G , TAN JUN
IPC分类号： A61K39/00 , A61K39/39 , A61P35/00 , A61P37/04
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/515 , A61K2039/5152 , A61K2039/5156 , A61K2039/53 , A61K2039/55522
摘要： A method of altering the specific, systemic immune response of an individual to an endogenous tumor or specific antigen by the administration, directly or as a gene-product, of a soluble form of CD40, optionally in combination with a cytokine and/or cell-based or isolated antigen. The target antigen may be a tumor cell, a tumor cell antigen, or other antigen to which a systemic immune response is desirable. Co-administration of a soluble form of CD40 and GM-CSF provides effective immunotherapy directed towards the treatment and/or prevention of otherwise poorly immunogenic tumors.
摘要翻译：通过直接或作为可溶性形式的CD40的任选地与细胞因子和/或细胞因子组合的CD40的可溶性形式，直接或作为基因产物来改变个体对内源性肿瘤或特异性抗原的特异性全身免疫应答的方法，基于或分离的抗原。靶抗原可以是肿瘤细胞，肿瘤细胞抗原或其中需要全身免疫应答的其它抗原。 CD40和GM-CSF的可溶形式的共同给药提供针对治疗和/或预防其他低免疫原性肿瘤的有效的免疫治疗。

9. 发明申请

WO2008005577A3 COMPOSITIONS OF POLYPHENOLS AND METHODS OF USE 审中-公开
标题翻译：多酚的组成和使用方法
公开(公告)号：WO2008005577A3
公开(公告)日：2008-02-21
申请号：PCT/US2007015684
申请日：2007-07-05
申请人： UNIV SOUTH FLORIDA , SHYTLE R DOUGLAS , TAN JUN
发明人： SHYTLE R DOUGLAS , TAN JUN
IPC分类号： A61K31/353 , A61K31/05 , A61P25/28
CPC分类号： A61K31/353 , A61K31/05
摘要： The subject invention concerns materials and methods for treating or preventing any condition or disease that is treatable by a green tea polyphenol, or an analog, isomer, metabolite, or prodrug thereof, wherein the polyphenol is administered as an intranasal formulation to a person or animal in need of treatment. In one embodiment, the intranasal polyphenol formulation comprises (-)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. The subject invention also concerns materials and methods for treating or preventing dementia, such as AIDS-dementia in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof. In one embodiment, a composition of the invention increases expression or activity of a protein that exhibits a-secretase activity.
摘要翻译：本发明涉及用于治疗或预防可通过绿茶多酚或其类似物，异构体，代谢物或前药治疗的任何病症或疾病的材料和方法，其中所述多酚作为鼻内制剂给予人或动物需要治疗。在一个实施方案中，鼻内多酚制剂包含（ - ） - 表没食子儿茶素-3-没食子酸酯（EGCG）和表儿茶素（EC），两种衍生自绿茶和其他植物的多酚，并且可以合成制备。本发明还涉及通过施用治疗有效量的多酚或其类似物，异构体，代谢物或前药来治疗或预防人或动物中的痴呆（例如AIDS-痴呆）的材料和方法。在一个实施方案中，本发明的组合物增加表现α-分泌酶活性的蛋白质的表达或活性。

10. 发明申请

WO2004037204A3 METHODS AND COMPOUNDS FOR DISRUPTION OF CD40R/CD40L SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
标题翻译： CD40R / CD40L信号治疗阿尔茨海默病的方法和化合物
公开(公告)号：WO2004037204A3
公开(公告)日：2006-05-26
申请号：PCT/US0333971
申请日：2003-10-27
申请人： UNIV SOUTH FLORIDA , TAN JUN , TOWN TERRENCE C , MULLAN MICHAEL J
发明人： TAN JUN , TOWN TERRENCE C , MULLAN MICHAEL J
IPC分类号： A61K20060101 , G01N33/50 , G01N33/53 , G01N33/567 , G01N33/68 , A01K67/00 , A01K67/033
CPC分类号： G01N33/5023 , G01N33/5041 , G01N33/6896 , G01N2333/70578 , G01N2800/2821
摘要： The present invention provides a research model for screening compounds suspected of modulating the CD40L/CD40R signaling pathway by interfering with the CD40L/CD40R signaling pathway in an animal or human. Additionally, methods are provided for causing a desired biological effect in an individual or system afflicted with neuronal inflammation, brain injury/trauma, a tauopathy, or an amyloidogenic disease, as well as for the identification of compounds and/or small molecules capable of disrupting the CD40L/CD40R signaling pathway.
摘要翻译：本发明提供了通过干扰动物或人类中的CD40L / CD40R信号通路来筛选疑似调节CD40L / CD40R信号通路的化合物的研究模型。此外，提供了用于在受神经元炎症，脑损伤/创伤，tau蛋白病或淀粉样变性疾病所折磨的个体或系统中产生所需生物学效应的方法，以及用于鉴定能够破坏的化合物和/或小分子 CD40L / CD40R信号通路。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式